Welcome to our dedicated page for Royalty Pharma news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma stock.
Royalty Pharma plc reports developments tied to its biopharmaceutical royalty portfolio and life-sciences funding model. The company acquires existing royalties from medicine innovators and enters direct funding arrangements, including co-funding for late-stage clinical trials and product launches, in exchange for future royalties.
Recurring news covers Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, royalty transactions, and updates from commercial products and development-stage candidates. Company announcements also address R&D funding collaborations, portfolio clinical and regulatory developments, leadership additions in partnering and technology, investor conference appearances, and scientific initiatives such as the Royalty Pharma Translational Prize.
Royalty Pharma (Nasdaq: RPRX) will present at two investor conferences in May 2026: BofA Securities Healthcare Conference on May 13, 2026 at 1:40 p.m. ET and RBC Capital Markets Global Healthcare Conference on May 19, 2026 at 10:00 a.m. ET.
Webcasts are available from the company’s Events page and will be archived for a minimum of 30 days.
Royalty Pharma (Nasdaq: RPRX) reported Q1 2026 results: Portfolio Receipts $925M (+10%), Royalty Receipts $887M (+13%), and net cash from operations $718M. The company announced up to $1.25B of new transactions and deployed $528M of capital. It raised full‑year 2026 Portfolio Receipts guidance to $3,325M–$3,450M and reported cash of $586M and debt principal of $9.2B.
Royalty Pharma (Nasdaq: RPRX) launched the Royalty Pharma Translational Prize, a new annual award to recognize translational medicine breakthroughs.
The Prize includes a $1 million award distributed among one or more established scientists; nominations open summer 2026 and the first laureate will be recognized in spring 2027 at the ABI conference.
Royalty Pharma (Nasdaq: RPRX) announced a $0.235 dividend per Class A ordinary share for Q2 2026. The dividend is payable on June 10, 2026 to shareholders of record at the close of business on May 15, 2026.
Royalty Pharma (Nasdaq: RPRX) will report first quarter 2026 financial results on Wednesday, May 6, 2026 before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time the same day.
Investors can find conference call details and access the live webcast via the company’s Investors events page. A replay will be archived on the website for at least 30 days.
Royalty Pharma (Nasdaq: RPRX) announced a research and development co-funding agreement with Johnson & Johnson totaling $500 million across 2026 and 2027 to advance JNJ-4804, an investigational co-antibody targeting IL-23 and TNF for chronic immune-mediated diseases.
The collaboration funds clinical development of JNJ-4804 and aligns Royalty Pharma with a major immunology partner while advisors Goodwin Procter served as legal counsel.
Royalty Pharma (Nasdaq: RPRX) appointed Lucas Glass as Head of Artificial Intelligence, effective April 2026.
The company said Glass will lead development and implementation of AI capabilities to support royalty evaluation, intelligent automation, advanced analytics and AI-driven decision support, drawing on more than a decade of life‑sciences AI and data experience and prior leadership at IQVIA.
Royalty Pharma (Nasdaq: RPRX) announced expansion of its leadership team, naming Greg Butz as Executive Vice President, Partnering & Investments, effective June 2026. The company also appointed Chris Hite as Chairman, Partnering & Investments and referenced Ken Sun's earlier addition as Head of Asia.
The hires aim to strengthen global origination and execution of royalty transactions, leveraging Butz's two decades of healthcare investment banking experience and Hite's relationship network.
Royalty Pharma (Nasdaq: RPRX) appointed Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Based in Hong Kong, he will lead the company’s royalty business across Asia and expand Royalty Pharma’s global platform.
The appointment follows significant regional deal flow: out‑licensing of Chinese medicines topped $130 billion in 2025, up from about $14 billion in 2021, creating a growing market opportunity for royalty‑based funding.
Royalty Pharma (Nasdaq: RPRX) agreed to provide $250 million to Zymeworks (Nasdaq: ZYME) via a non‑recourse royalty‑backed note secured by 30% of worldwide tiered royalties on Ziihera until repayment.
Repayment ends when Royalty Pharma receives 1.65x the note by Dec 31, 2033, or 1.925x thereafter; Zymeworks retains 70% royalties and all milestone payments up to $1.5 billion potential remaining. Proceeds fund share repurchases, potential acquisitions, and cash runway beyond 2028.